Royalty Pharma (NASDAQ: RPRX) holder plans multi-million share sale

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) received a notice that SCH Investment Partners LLC intends to sell 100,000 Class A Ordinary Shares of Royalty Pharma under Rule 144. These shares, acquired in private transactions in 2024 and 2025, have an aggregate market value of $6,012,000. Royalty Pharma had 445,277,344 shares outstanding as of the notice date. SCH Investment Partners LLC previously sold 150,000 shares for $8,166,766.13 on June 23, 2026 and 100,000 shares for $5,645,700.97 on June 30, 2026, all under a selling plan dated March 20, 2026 intended to comply with Rule 10b5-1(c).

Key Figures

Shares to be sold: 100,000 shares Aggregate market value of shares to be sold: $6,012,000 Shares outstanding: 445,277,344 shares +3 more

6 metrics

Shares to be sold 100,000 shares Class A Ordinary Shares of Royalty Pharma covered by this Form 144 notice

Aggregate market value of shares to be sold $6,012,000 Market value of 100,000 Class A Ordinary Shares subject to proposed Rule 144 sale

Shares outstanding 445,277,344 shares Royalty Pharma Class A Ordinary Shares outstanding as referenced in the notice

Sale on June 23, 2026 150,000 shares for $8,166,766.13 Shares sold by SCH Investment Partners LLC during the past 3 months

Sale on June 30, 2026 100,000 shares for $5,645,700.97 Additional shares sold by SCH Investment Partners LLC during the past 3 months

Selling plan date 03/20/2026 Date of selling plan intended to comply with Rule 10b5-1(c)

Key Terms

Rule 144, Rule 10b5-1(c), selling plan

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Rule 10b5-1(c) regulatory

"selling plan dated 03/20/2026, which is intended to comply with Rule 10b5-1(c)."

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

selling plan financial

"sales of shares set forth herein are made in connection with a selling plan dated 03/20/2026"

FAQ

What does the Form 144 filing mean for Royalty Pharma plc (RPRX)?

The filing reports that SCH Investment Partners LLC plans to sell 100,000 Class A Ordinary Shares of Royalty Pharma under Rule 144. This is a resale by an existing holder and does not represent a new share issuance by Royalty Pharma.

How many RPRX shares is SCH Investment Partners LLC planning to sell?

SCH Investment Partners LLC plans to sell 100,000 Class A Ordinary Shares of Royalty Pharma. These shares were acquired from the issuer in private transactions in May 2024 and February 2025, totaling the 100,000 shares covered by this notice.

What is the market value of the Royalty Pharma (RPRX) shares covered by this Form 144?

The 100,000 Royalty Pharma Class A Ordinary Shares covered by the notice have an aggregate market value of $6,012,000. This value is based on the pricing information provided in the Form 144 at the time of the notice filing.

How many Royalty Pharma (RPRX) shares are outstanding as referenced in the Form 144?

The Form 144 states that 445,277,344 Royalty Pharma Class A Ordinary Shares were outstanding as of the notice date. This figure provides context for the size of the 100,000-share planned sale relative to the total share base.

What prior sales of RPRX shares did SCH Investment Partners LLC report in the last three months?

SCH Investment Partners LLC reported selling 150,000 Royalty Pharma shares for $8,166,766.13 on June 23, 2026 and 100,000 shares for $5,645,700.97 on June 30, 2026. These transactions were also made under the same Rule 10b5-1(c) selling plan.

Is the planned sale of Royalty Pharma (RPRX) shares under a Rule 10b5-1 trading plan?

Yes. The Form 144 specifies that the sales described are made pursuant to a selling plan dated March 20, 2026, which is intended to comply with Rule 10b5-1(c), governing pre-arranged trading plans for securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:46 PM Accepted by SEC EDGAR 08/18/2026 - 04:45 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002094176
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Royalty Pharma PLC
SEC File Number	001-39329
Address of Issuer	110 East 59th Street New York NEW YORK 10022
Phone	212-883-0200
Name of Person for Whose Account the Securities are To Be Sold	SCH Investment Partners LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A Ordinary Shares	Merrill Lynch One Byrant Park New York NY 10036	100000	6012000	445277344	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A Ordinary Shares	02/14/2025	Acquired from issuer in private transaction	Issuer			75000	02/14/2025	N/A
Class A Ordinary Shares	05/13/2024	Acquired from issuer in private transaction	Issuer			25000	05/13/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
SCH Investment Partners LLC 110 E 59th Street New York NY 10022	Class A Ordinary Shares	06/23/2026	150000	8166766.13
SCH Investment Partners LLC 110 E 59th Street New York NY 10022	Class A Ordinary Shares	06/30/2026	100000	5645700.97

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 03/20/2026, which is intended to comply with Rule 10b5-1(c).
Date of Notice	08/18/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/20/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Christopher Hite
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)